BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Oleclumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Oleclumab\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05221840-2157@assetmemo.bio
DTSTAMP:20261121T005608Z
DTSTART;VALUE=DATE:20270108
DTEND;VALUE=DATE:20270109
SUMMARY:Oleclumab: Phase 3 readout est. (NCT05221840)
DESCRIPTION:Oleclumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Glo
 bal Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab
  With Monalizumab Following Concurrent Chemoradiation in Patients With Sta
 ge III Unresectable Non-Small Cell Lung Cancer\nEstimated primary completi
 on: 8 January 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/o
 leclumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05221840
URL:https://assetmemo.bio/drug/oleclumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04668300-2157@assetmemo.bio
DTSTAMP:20261121T005608Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Oleclumab: Phase 2 readout est. (NCT04668300)
DESCRIPTION:Oleclumab\, phase 2.\nStudy: Oleclumab and Durvalumab for the T
 reatment of Recurrent\, Refractory\, or Metastatic Sarcoma\nEstimated prim
 ary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/oleclumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04668300
URL:https://assetmemo.bio/drug/oleclumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04940286-2157@assetmemo.bio
DTSTAMP:20261121T005608Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Oleclumab: Phase 2 readout est. (NCT04940286)
DESCRIPTION:Oleclumab\, phase 2.\nStudy: Gemcitabine\, Nab-paclitaxel\, Dur
 valumab\, and Oleclumab Before Surgery for the Treatment of in Resectable/
 Borderline Resectable Primary Pancreatic Cancer\nEstimated primary complet
 ion: 30 October 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /oleclumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT04940286
URL:https://assetmemo.bio/drug/oleclumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07146230-2157@assetmemo.bio
DTSTAMP:20261121T005608Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Oleclumab: Phase 2 readout est. (NCT07146230)
DESCRIPTION:Oleclumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: The S
 elective Personalized Radio-Immunotherapy for Locally Advanced Non-Small C
 ell Lung Cancer Trial 2\nEstimated primary completion: April 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/oleclumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07146230
URL:https://assetmemo.bio/drug/oleclumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05061550-2157@assetmemo.bio
DTSTAMP:20261121T005608Z
DTSTART;VALUE=DATE:20300528
DTEND;VALUE=DATE:20300529
SUMMARY:Oleclumab: Phase 2 readout est. (NCT05061550)
DESCRIPTION:Oleclumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoad
 juvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer\nEs
 timated primary completion: 28 May 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/oleclumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05061550
URL:https://assetmemo.bio/drug/oleclumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
